Role of diuretics and lipid formulations in the prevention of amphotericin B-induced nephrotoxicity

European Journal of Clinical Pharmacology

Volumn 69, Issue 7, 2013, Pages 1351-1368

  Karimzadeh, Iman ^a   Khalili, Hossein ^a   Farsaei, Shadi ^a   Dashti Khavidaki, Simin ^a   Sagheb, Mohammad Mahdi ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Amphotericin; Nephrotoxicity; Prevention

Indexed keywords

AMILORIDE; AMINOGLYCOSIDE DERIVATIVE; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CISPLATIN; CREATININE; CYCLOSPORIN; GLUCOSE; INTRALIPID; MANNITOL; OSMOTIC DIURETIC AGENT; PLATINUM DERIVATIVE; POTASSIUM; POTASSIUM SPARING DIURETIC AGENT; SOYBEAN OIL; SPIRONOLACTONE; VANCOMYCIN;

ABSENCE OF SIDE EFFECTS; ADULT RESPIRATORY DISTRESS SYNDROME; AREA UNDER THE CURVE; ASPERGILLOSIS; CANCER PATIENT; CANDIDEMIA; CANDIDIASIS; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; CRYPTOCOCCAL MENINGITIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG SOLUBILITY; DRUG SYNTHESIS; DRUG TOLERANCE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; FEBRILE NEUTROPENIA; HISTOPLASMOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERKALEMIA; HYPERNATREMIA; HYPEROSMOLARITY; HYPERVOLEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOVOLEMIA; IMMUNOCOMPROMISED PATIENT; LOW DRUG DOSE; LUNG DISEASE; LUNG FIBROSIS; LUNG TOXICITY; METABOLIC ACIDOSIS; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; PARTICLE SIZE; PATIENT MONITORING; PLEURISY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; RENAL PROTECTION; REVIEW; SIDE EFFECT; SYSTEMIC MYCOSIS; THORAX PAIN; THRUSH; TREATMENT DURATION; UREA NITROGEN BLOOD LEVEL; UREMIA; VISCERAL LEISHMANIASIS;

AMPHOTERICIN B; ANIMALS; ANTI-INFECTIVE AGENTS; COLLOIDS; DIURETICS; HUMANS; HYPOKALEMIA; LIPIDS; LIPOSOMES; PHARMACEUTICAL VEHICLES; RENAL INSUFFICIENCY;

EID: 84879068575     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-013-1472-1     Document Type: Review

References (103)

1. Laniado-Laborín R, Cabrales-Vargas MN (2009) Amphotericin B: side effects and toxicity. RevI beroam Micol 26:223-227
2. Ulozas E (2010) Amphotericin B-induced nephrotoxicity. Compr Toxicol 7:347-357
3. Gallis HA, Drew RH, Pickard WW (1990) Amphotericin B: 30 years of clinical experience. Rev Infect Dis 12:308-329
4. Anderson CM (1995) Sodium chloride treatment of amphotericin B nephrotoxicity-standard of care? West J Med 162:313-317
5. Harbarth S, Pestotnik SL, Lloyd JF, Burke JP, Samore MH (2001) The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. Am J Med 111:528-534
6. Fanos V, Cataldi L (2000) Amphotericin B-induced nephrotoxicity: a review. J Chemother 12(6):463-470
7. Goldman RD, Koren G (2004) Amphotericin B nephrotoxicity in children. J Pediatr Hematol Oncol 26:421-426
8. Atsmon J, Dolev E (2005) Drug-induced hypomagnesaemia: scope and management. Drug Saf 28:763-788
9. Llanos A, Cieza J, Bernardo J et al (1991) Effect of salt supplementation on amphotericin B nephrotoxicity. Kidney Int 40:302-308
10. Wazny LD, Brophy DF (2000) Amiloride for the prevention of amphotericin B-induced hypokalemia and hypomagnesemia. Ann Pharmacother 34:94-97
11. Bates DW, Su L, Yu DT et al (2001) Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 32:686-693
12. Karimzadeh I, Farsaei S, Khalili H, Dashti-Khavidaki S (2012) Are salt loading and prolonging infusion period effective in prevention of amphotericin B-induced nephrotoxicity? Expert Opin Drug Saf 11:969-983
13. Venkataraman R, Kellum JA (2007) Prevention of acute renal failure. Chest 131:300-308
14. Nigwekar SU, Waikar SS (2011) Diuretics in acute kidney injury. Semin Nephrol 31:523-534
15. Hellebusch AA, Salama F, Eadie E (1972) The use of mannitol to reduce the nephrotoxicity of amphotericin B. Surg Gynecol Obstet 134:241-243
16. Rosch JM, Pazin GJ, Fireman P (1976) Reduction of amphotericin B nephrotoxicity with mannitol. JAMA 235:1995-1996
17. Olivero JJ, Lozano-Mendez J, Ghafary EM, Eknoyan G, Suki WN (1975) Mitigation of amphotericin B nephrotoxicity by mannitol. Br Med J 1:550-551
18. Bullock WE, Luke RG, Nuttall CE, Bhathena D (1976) Can mannitol reduce amphotericin B nephrotoxicity? Double-blind study and description of a new vascular lesion in kidneys. Antimicrob Agents Chemother 10:555-563
19. Cvitkovic E, Spaulding J, Bethune V, Martin J, Whitmore WF (1977) Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model. Cancer 39:1357-1361
20. Al-Sarraf M, Fletcher W, Oishi N, Pugh R, Hewlett JS, Balducci L, McCracken J, Padilla F (1982) Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a southwest oncology group study. Cancer Treat Rep 66:31-35
21. Smith SR, Galloway MJ, Reilly JT, Davies JM (1988) Amiloride prevents amphotericin B related hypokalaemia in neutropenic patients. J Clin Pathol 41:494-497
22. Bearden DT, Muncey LA (2001) The effect of amiloride on amphotericin B-induced hypokalaemia. J Antimicrob Chemother 48:109-111
23. Epstein M, Calhoun DA (2011) Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics. J Clin Hypertens (Greenwich) 13:644-648
24. Ural AU, Avcu F, Cetin T, Beyan C, Kaptan K, Nazaroglu NK, Yalcin A (2002) Spironolactone: is it a novel drug for the prevention of amphotericin B-related hypokalemia in cancer patients? Eur J Clin Pharmacol 57:771-773
25. Hippalgaonkar K, Majumdar S, Kansara V (2010) Injectable lipid emulsions-advancements, opportunities and challenges. AAPS PharmSciTech 11:1526-1540
26. Kirsh R, Goldstein R, Tarloff J, Parris D, Hook J, Hanna N, Bugelski P, Poste G (1988) An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis. J Infect Dis 158:1065-1070
27. Moreau P, Milpied N, Fayette N, Ramée JF, Harousseau JL (1992) Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients. J Antimicrob Chemother 30:535-541
28. Pascual B, Ayestaran A, Montoro JB, Oliveras J, Estibalez A, Julia A, Lopez A (1995) Administration of lipid-emulsion versus conventional amphotericin B in patients with neutropenia. Ann Pharmacother 29:1197-1201
29. Caillot D, Casasnovas O, Solary E, Chavanet P, Bonnotte B, Reny G, Entezam F, Lopez J, Bonnin A, Guy H (1993) Efficacy and tolerance of an amphotericin B lipid (Intralipid) emulsion in the treatment of candidaemia in neutropenic patients. J Antimicrob Chemother 31:161-169
30. Schöffski P, Freund M, Wunder R, Petersen D, Köhne CH, Hecker H, Schubert U, Ganser A (1998) Safety and toxicity of amphotericin B in glucose 5 % or intralipid 20 % in neutropenic patients with pneumonia or fever of unknown origin: randomised study. Br Med J 317:379-384
31. Caillot D, Reny G, Solary E, Casasnovas O, Chavanet P, Bonnotte B, Perello L, Dumas M, Entezam F, Guy H (1994) A controlled trial of the tolerance of amphotericin B infused in dextrose or in Intralipid in patients with haematological malignancies. J Antimicrob Chemother 33:603-613
32. Nucci M, Loureiro M, Silveira F, Casali AR, Bouzas LF, Velasco E, Spector N, Pulcheri W (1999) Comparison of the toxicity of amphotericin B in 5 % dextrose with that of amphotericin B in fat emulsion in a randomized trial with cancer patients. Antimicrob Agents Chemother 43:1445-1448
33. Nath CE, Shaw PJ, Gunning R, McLachlan AJ, Earl JW (1999) Amphotericin B in children with malignant disease: a comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion. Antimicrob Agents Chemother 43:1417-1423
34. Trissel LA (1995) Amphotericin B does not mix with fat emulsion. Am J Health Syst Pharm 52:1463-1464
35. Chavanet PY, Garry I, Charlier N, Caillot D, Kisterman JP, D'Athis M, Portier H (1992) Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis. Br Med J 305:921-925
36. Chavanet P, Clement C, Duong M, Buisson M, D'Athis P, Dumas M, Bonnin A, Portier H (1997) Toxicity and efficacy of conventional amphotericin B deoxycholate versus escalating doses of amphotericin B deoxycholate-fat emulsion in HIV-infected patients with oral candidosis. Clin Microbiol Infect 3:455-461
37. Joly V, Aubry P, Ndayiragide A, Carrière I, Kawa E, Mlika-Cabanne N, Aboulker JP, Coulaud JP, Larouze B, Yeni P (1996) Randomized comparison of amphotericin B deoxycholate dissolved in dextrose or Intralipid for the treatment of AIDS-associated cryptococcal meningitis. Clin Infect Dis 23:556-562
38. Sorkine P, Nagar H, Weinbroum A, Setton A, Israitel E, Scarlatt A, Silbiger A, Rudick V, Kluger Y, Halpern P (1996) Administration of amphotericin B in lipid emulsion decreases nephrotoxicity: results of a prospective, randomized, controlled study in critically ill patients. Crit Care Med 24:1311-1315
39. Barquist E, Fein E, Shadick D, Johnson J, Clark J, Shatz D (1999) A randomized prospective trial of amphotericin B lipid emulsion versus dextrose colloidal solution in critically ill patients. J Trauma 47:336-340
40. Thakur CP (1994) Comparison of glucose versus fat emulsion in the preparation of amphotericin B for use in kala-azar. Trans R Soc Trop Med Hyg 88:698-699
41. Sundar S, Chakravarty J, Agarwal D, Shah A, Agrawal N, Rai M (2008) Safety of a pre-formulated amphotericin B lipid emulsion for the treatment of Indian Kala-azar. Trop Med Int Health 13:1208-1212
42. Sundar S, Singh A, Agarwal D, Rai M, Agrawal N, Chakravarty J (2009) Safety and efficacy of high-dose infusions of a preformed amphotericin B fat emulsion for treatment of Indian visceral leishmaniasis. Am J Trop Med Hyg 80:700-703
43. Salama S, Rotstein C (1997) Reduction in the nephrotoxicity of amphotericin B when administered in 20 % intralipid. Can J Infect Dis 8:157-160
44. Anderson RP, Clark DA (1995) Amphotericin B toxicity reduced by administration in fat emulsion. Ann Pharmacother 29:496-500
45. Mistro S, Maciel Ide M, de Menezes RG, Maia ZP, Schooley RT, Badaró R (2012) Does lipid emulsion reduce amphotericin B nephrotoxicity? A systematic review and meta-analysis. Clin Infect Dis 54:1774-1777
46. Ericsson O, Hallmen AC, Wikstrom I (1996) Amphotericin B is incompatible with lipid emulsions. Ann Pharmacother 30:298
47. Cleary JD (1996) Amphotericin B formulated in a lipid emulsion. Ann Pharmacother 30:409-412
48. Heide PE (1997) Precipitation of amphotericin B from i.v. fat emulsion. Am J Health Syst Pharm 54:1449
49. National Library of Medicine, National Institutes of Health. Intralipid (soybean oil) emulsion. Available at: http://dailymed.nlm.nih.gov/dailymed/ drugInfo.cfm?id = 6275. Accessed 4 May 2012
50. Johnson RH, Einstein HE (2007) Amphotericin B and coccidioidomycosis. Ann N Y Acad Sci 1111:434-441
51. Kobayashi GS, Little JR, Medoff G (1985) In vitro and in vivo comparisons of amphotericin B and N-D-ornithyl amphotericin B methyl ester. Antimicrob Agents Chemother 27:302-305
52. BanghamA D, Hill MW, Miller NGA (1974) Preparationa nd use of liposomes as models of biological membranes. In: KornE D (ed) Methods in membrane biology, vol 1. Plenum Press, New York, pp 1-68
53. White MH, Bowden RA, Sandler ES, Graham ML, Noskin GA, Wingard JR, Goldman M, van Burik JA, McCabe A, Lin JS, Gurwith M, Miller CB (1998) Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 27:296-302
54. White MH, Anaissie EJ, Kusne S, Wingard JR, Hiemenz JW, Cantor A, Gurwith M, Du Mond C, Mamelok RD, Bowden RA (1997) Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis 24:635-642
55. Slain D (1999) Lipid-based amphotericin B for the treatment of fungal infections. Pharmacotherapy 19:306-323
56. Mehta R, Lopez-Berestein G, Hopfer R, Mills K, Juliano RL (1984) Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells. Biochim Biophys Acta 770:230-234
57. Proffitt RT, Satorius A, Chiang SM, Sullivan L, Adler-Moore JP (1991) Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. J Antimicrob Chemother 28[Suppl B]:49-61
58. Lee JW, Amantea MA, Francis PA, Navarro EE, Bacher J, Pizzo PA, Walsh TJ (1994) Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimicrob Agents Chemother 38:713-718
59. Wasan KM, Rosenblum MG, Cheung L, Lopez-Berestein G (1994) Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B. Antimicrob Agents Chemother 38:223-227
60. Perkins WR, Minchey SR, Boni LT, Swenson CE, Popescu MC, Pasternack RF, Janoff AS (1992) Amphotericin B-phospholipid interactions responsible for reduced mammalian cell toxicity. Biochim Biophys Acta 1107:271-282
61. Prentice HG, Hann IM, Herbrecht R, Aoun M, Kvaloy S, Catovsky D, Pinkerton CR, Schey SA, Jacobs F, Oakhill A, Stevens RF, Darbyshire PJ, Gibson BE (1997) A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 98:711-718
62. Leenders AC, Daenen S, Jansen RL, Hop WC, Lowenberg B, Wijermans PW, Cornelissen J, Herbrecht R, van der Lelie H, Hoogsteden HC, Verbrugh HA, de Marie S (1998) Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 103:205-212
63. Walsh TJ, Finberg RW, Arndt C et al (1999) Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 340:764-771
64. Johnson PC, Wheat LJ, Cloud GA, Goldman M, Lancaster D, Bamberger DM, Powderly WG, Hafner R, Kauffman CA, Dismukes WE, U.S. National Institute of Allergy and Infectious Diseases Mycoses Study Group (2002) Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med 137:105-109
65. Sharkey PK, Graybill JR, Johnson ES, Hausrath SG, Pollard RB, Kolokathis A, Mildvan D, Fan-Havard P, Eng RH, Patterson TF, Pottage JC Jr, Simberkoff MS, Wolf J, Meyer RD, Gupta R, Lee LW, Gordon DS (1996) Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 22:315-321
66. Clark JM, Whitney RR, Olsen SJ, George RJ, Swerdel MR, Kunselman L, Bonner DP (1991) Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob Agents Chemother 35:615-621
67. Coker RJ, Viviani M, Gazzard BG, Du Pont B, Pohle HD, Murphy SM, Atouguia J, Champalimaud JL, Harris JR (1993) Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS. AIDS 7:829-835
68. Subirà M, Martino R, Gómez L, Martí JM, Estany C, Sierra J (2004) Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies-a randomized, controlled trial. Eur J Haematol 72:342-347
69. Malani PN, Depestel DD, Riddell J, Bickley S, Klein LR, Kauffman CA (2005) Experience with community-based amphotericin B infusion therapy. Pharmacotherapy 25:690-697
70. Ullmann AJ, Sanz MA, Tramarin A, Barnes RA, Wu W, Gerlach BA, Krobot KJ, Gerth WC, Longitudinal Evaluation of Antifungal Drugs (LEAD I) Investigators (2006) Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries. Clin Infect Dis 43:e29-e38
71. Clark AD, McKendrick S, Tansey PJ, Franklin IM, Chopra R (1998) A comparative analysis of lipid-complexed and liposomal amphotericin B preparations in haematological oncology. Br J Haematol 103:198-204
72. Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A, L Amph/ABLC Collaborative Study Group (2000) A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 31:1155-1163
73. Fleming RV, Kantarjian HM, Husni R, Rolston K, Lim J, Raad I, Pierce S, Cortes J, Estey E (2001) Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk Lymphoma 40:511-520
74. Cannon JP, Garey KW, Danziger LH (2001) A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations. Pharmacotherapy 21:1107-1114
75. Mattiuzzi GN, Kantarjian H, Faderl S, Lim J, Kontoyiannis D, Thomas D, Wierda W, Raad I, Garcia-Manero G, Zhou X, Ferrajoli A, Bekele N, Estey E (2004) Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy. Cancer 100:581-589
76. Hachem RY, Boktour MR, Hanna HA, Husni RN, Torres HA, Afif C, Kontoyiannis DP, Raad II (2008) Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy. Cancer 112:1282-1287
77. Costa S, Nucci M (2001) Can we decrease amphotericin nephrotoxicity? Curr Opin Crit Care 7:379-383
78. Johansen HK, Gotzsche PC (2000) Amphotericin B lipid soluble formulations vs amphotericin B in cancer patients with neutropenia. Cochrane Database Syst Rev 2000(3):CD000969
79. Macauly SS, Martin JE, Zarnke KB (2002) Amphotericin B for the treatment of systemic fungal infections: meta-analysis of conventional versus lipid formulations. In: Interscience Conf on Antimicrobial Agents and Chemotherapy. 42nd ICAAC, San Diego, CA, Abstract - 888
80. Barrett JP, Vardulaki KA, Conlon C, Cooke J, Daza-Ramirez P, Evans EG, Hawkey PM, Herbrecht R, Marks DI, Moraleda JM, Park GR, Senn SJ, Viscoli C, Amphotericin B Systematic Review Study Group (2003) A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther 25:1295-1320
81. Martino R (2004) Efficacy, safety and cost-effectiveness of Amphotericin B Lipid Complex (ABLC): a review of the literature. Curr Med Res Opin 20:485-504
82. Moen MD, Lyseng-Williamson KA, Scott LJ (2009) Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs 69:361-392
83. Safdar A, Ma J, Saliba F, Dupont B, Wingard JR, Hachem RY, Mattiuzzi GN, Chandrasekar PH, Kontoyiannis DP, Rolston KV, Walsh TJ, Champlin RE, Raad II (2010) Drug-induced nephrotoxicity caused by amphotericin B lipid complex and liposomal amphotericin B: a review and meta-analysis. Medicine 89:236-244
84. Wong-Beringer A, Jacobs RA, Guglielmo BJ (1998) Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 27:603-618
85. Matot I, Pizov R (2000) Pulmonary extraction and accumulation of lipid formulations of amphotericin B. Crit Care Med 28:2528-2532
86. Hovsepian M, Lee P, Goldstein B (1999) Comparison of safety and cost-effectiveness of Abelcet and Amphotec. American Society of Hospital Pharmacists, Las Vegas
87. Greenberg RN, Cagnoni PJ, Prendergast MM, Tong KB (2000) Pharmacoeconomics of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of persistently febrile neutropenic patients. In: Interscience Conf on Antimicrobial Agents and Chemotherapy. 40th ICAAC, Toronto, CA, Abstract - 506
88. Osswald H, Nabakowski G, Hermes H (1980) Adenosine as a possible mediator of metabolic control of glomerular filtration rate. Int J Biochem 12:263-267
89. Gerkens JF, Heidemann HT, Jackson EK, Branch RA (1983) Effect of aminophylline on amphotericin B nephrotoxicity in the dog. J Pharmacol Exp Ther 224:609-613
90. Heidemann HT, Gerkens JF, Jackson EK, Branch RA (1983) Effect of aminophylline on renal vasoconstriction produced by amphotericin B in the rat. Naunyn Schmiedebergs Arch Pharmacol 324:148-152
91. Kuan CJ, Branch RA, Jackson EK (1990) Effect of an adenosine receptor antagonist on acute amphotericin B nephrotoxicity. Eur J Pharmacol 178:285-291
92. Brooks DP, Mitchell MP, Short BG, Ruffolo RR Jr, Nichols AJ (1991) Attenuation of amphotericin B nephrotoxicity in the dog by the fenoldopam prodrug, SK&F R-105058. J Pharmacol Exp Ther 257:1243-1247
93. Nichols AJ, Koster PF, Brooks DP, Ruffolo RRJR (1992) Effect of fenoldopam on the acute and subacute nephrotoxicity produced by amphotericin B in the dog. J Pharmacol Exp Ther 260:269-274
94. Soupart A, Decaux G (1989) Nifedipine and amphotericin B nephrotoxicity in the rat. Nephron 52:278-280
95. Zager RA, Bredl CR, Schimpf BA (1992) Direct amphotericin B-mediated tubular toxicity: assessments of selected cytoprotective agents. Kidney Int 41:1588-1594
96. Tolins JP, Raij L (1991) Chronic amphotericin B nephrotoxicity in the rat: protective effect of calcium channel blockade. Am Soc Nephrol 2:98-102
97. Varlam DE, Siddiq MM, Parton LA, Rüssmann H (2001) Apoptosis contributes to amphotericin B-induced nephrotoxicity. Antimicrob Agents Chemother 45:679-685
98. Sheikh-Hamad D, Timmins K, Jalali Z (1997) Cisplatin-induced renal toxicity: possible reversal by N-acetylcysteine treatment. J Am Soc Nephrol 8:1640-1644
99. Tariq M, Morais C, Sobki S, Al Sulaiman M, Al Khader A (1999) N-acetylcysteine attenuates cyclosporin-induced nephrotoxicity in rats. Nephrol Dial Transplant 14:923-929
100. Mazzon E, Britti D, De Sarro A, Caputi AP, Cuzzocrea S (2001) Effect of N-acetylcysteine on gentamicin-mediated nephropathy in rats. Eur J Pharmacol 424:75-83
101. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W (2000) Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 343:180-184
102. Feldman L, Efrati S, Dishy V, Katchko L, Berman S, Averbukh M, Aladjem M, Averbukh Z, Weissgarten J (2005) N-acetylcysteine ameliorates amphotericin-induced nephropathy in rats. Nephron Physiol 99:23-27
103. Odabasi Z, Karaalp A, Cermik H, Mohr J, Tigen ET, Koc M, Korten V (2009) Reduction of amphotericin B-induced renal tubular apoptosis by N-acetylcysteine. Antimicrob Agents Chemother 53:3100-3102